De hyppigheder, der er typiske for lægemidler i gruppen af tetracykliner, vil optræde med mindre sandsynlighed under medicinering med ORACEA på grund af den reducerede dosering og de relativt lave plasmaniveauer.
Adverse reactions typical of the tetracycline class of medicinal products are less likely to occur during medication with ORACEA, due to the reduced dosage and the relatively low plasma levels involved.